From ideas...to medical applications
In the absence of any straightforward laboratory tests, the most severe complication, known as type II heparin-induced thrombocytopenia (HIT) has...
From ideas...to medical applications
Midway between plasma haemostasis and cellular haemostasis are microparticles, rich in procoagulant phospholipids. An increase in this procoagulant...
From ideas...to medical applications
Listening to and exchanging ideas with members of the biomedical science community has enabled Stago to develop its expertise in the search for...
From ideas...to medical applications
Achieving a balanced policy with regard to investment in research & development (R&D), technological monitoring and rational acquisitions is a key...
April 25 - 28, 2012
May 9 - 11, 2012
May 21 - 24, 2012
STA®-Rivaroxaban Calibrator & STA®-Rivaroxaban Control (CE marking)
Rivaroxaban is a new oral anticoagulant, direct factor Xa inhibitor, developed by Bayer HealthCare and sold under the trade name Xarelto®. It is approved in three indications in Europe: prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors, treatment of deep vein thrombosis (DVT) and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT in adults and prevention of VTE in adult patients undergoing elective hip or knee replacement surgery.
Heparin was discovered independently in 1911 by Doyon and in 1916 by McLean, for different reasons. The effect of heparin on blood clotting, however, had been observed one-third of a century earlier.
